WO2012027972A1 - FORME CRISTALLINE α DU TÉNOFOVIR DISOPROXIL FUMARATE, PROCÉDÉ POUR LA PRÉPARER ET SON UTILISATION - Google Patents

FORME CRISTALLINE α DU TÉNOFOVIR DISOPROXIL FUMARATE, PROCÉDÉ POUR LA PRÉPARER ET SON UTILISATION Download PDF

Info

Publication number
WO2012027972A1
WO2012027972A1 PCT/CN2011/070142 CN2011070142W WO2012027972A1 WO 2012027972 A1 WO2012027972 A1 WO 2012027972A1 CN 2011070142 W CN2011070142 W CN 2011070142W WO 2012027972 A1 WO2012027972 A1 WO 2012027972A1
Authority
WO
WIPO (PCT)
Prior art keywords
tenofovir disoproxil
disoproxil fumarate
crystalline form
solvent
tenofovir
Prior art date
Application number
PCT/CN2011/070142
Other languages
English (en)
Chinese (zh)
Inventor
姜维斌
倪晟
赵航
Original Assignee
杭州和素化学技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 杭州和素化学技术有限公司 filed Critical 杭州和素化学技术有限公司
Publication of WO2012027972A1 publication Critical patent/WO2012027972A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Definitions

  • the present invention relates to an antiviral drug tenofovir disoproxil fumarate ((R)-[[2-(6-amino-9 ⁇ - ⁇ -9-yl)-1-indolylethoxy]indolyl] A new crystalline form of diisopropoxycarbonyl oxime ester fumarate) and a process for the preparation of the novel crystalline form and its use in pharmaceutical formulations.
  • Tenofovir disoproxil fumarate (TDF), chemical name (R)-[[2-(6-amino-9H- ⁇ -9-yl)-1-indolylethoxy] ⁇ Phosphonic acid diisopropoxycarbonyloxy oxime fumarate, which has the structure shown in formula (I), was developed by Glead Sciences, USA, and was first marketed in the United States in October 2001. It is now in Europe. Listed in countries such as Australia and Canada. At the 58th Annual Meeting of the American Association for the Study of Liver Diseases in November 2007 and the 43rd European Conference on Liver Diseases in 2008-04, reports on the treatment of chronic hepatitis B CHB with tenofovir have attracted widespread attention.
  • Tenofovir fumarate is a novel nucleoside (acid) analog that was approved by the US Food and Drug Administration (FDA) in 2001 for HIV infection. It is hydrolyzed in vivo to give tenofovir, a medicinal ingredient (structure is shown in formula (III)). It is able to significantly inhibit the activity of HBV replication in vitro, so it is hopeful to become a member of HAART therapy for HIV/HBV co-infection.
  • TDF is a prodrug of tenofovir and is a novel acyclic nucleoside (acid) analog that has anti-HIV-1 and HIV-2 activity in vitro.
  • TDF is one of the widely used nucleoside (acid) reverse enzyme inhibitors for the treatment of HIV. Its outstanding effect, good applicability and proper dosage make him the most popular therapeutic drug in the first line, and have been recommended by the 4 ⁇ multi-guideline as a better nucleoside (acid) reversal enzyme inhibition for first-line antiviral therapy. Use of the agent.
  • Viread tenofovir disoproxil fumarate
  • Viread tenofovir disoproxil fumarate
  • tenofovir is significantly more effective than adefovir in the treatment of chronic hepatitis B.
  • Form A XRD characteristic peaks are expressed at about 2,, 7.0, 10.7, 11.9, 12.9, 13.7, 15.2, 15.6, 16.4, 19.0, 20.3, 21.5, 22.3, 25.5, 26.0, 27.4, 30.7 and 31.1 and
  • the DSC differential heat absorption peak is about 113.1 °C;
  • Form B XRD characteristic peaks are expressed at about 2, 3, 3, 11.3, 11.2, 14.2, 15.4, 16.2, 18.2, 19.0, 20.6, 25.8, and 31.0 and the DSC differential heat absorption peak is about 115.5 °C.
  • the invention content is expressed at about 2, 3, 3, 11.3, 11.2, 14.2, 15.4, 16.2, 18.2, 19.0, 20.6, 25.8, and 31.0 and the DSC differential heat absorption peak is about 115.5 °C.
  • the first technical problem to be solved by the present invention is to provide a novel crystalline form of tenofovir disoproxil fumarate which we have named as the alpha crystalline form.
  • the new crystalline form is substantially free of water and crystalline forms of other solvents, and this crystalline form can satisfy the performance required for large scale synthesis or formulation into therapeutic formulations.
  • the tenofovir fumarate alpha form of the present invention using Cu-Ka radiation, has an X-ray powder diffraction spectrum expressed at a angle of 2 ⁇ of about 7.1, about 7.8, about 8.1, about 9.8, about 10.5, About 10.9, about
  • differential thermal analysis pattern of the ⁇ crystal form has an endothermic peak at about 117.4 °C.
  • the infrared spectrum of the ⁇ crystal form is about 3198 cm- 1 at about SSS cm- 1 .
  • a second technical problem to be solved by the present invention is to provide a method for preparing a crystalline form of tenofovir disoproxil fumarate which can be used for large-scale industrial production.
  • a method for preparing a crystalline form of tenofovir disoproxil fumarate comprises the following steps:
  • the first solvent is selected from the group consisting of one or any combination of the following: a C1-C6 alcohol solvent (including a linear alkane alcohol and a Side chain alkane alcohol),
  • the step (1) of the present invention in consideration of the need for solvent recovery in production, it is preferred to use a single solvent for dissolution, and in particular, a common solvent such as decyl alcohol, ethanol, isopropanol, ethyl acetate or acetone may be used.
  • a common solvent such as decyl alcohol, ethanol, isopropanol, ethyl acetate or acetone may be used.
  • the crystal form is dissolved.
  • the volume of the first solvent is 10 to 50 mL/g, preferably 20 to 30 mL/g, based on the mass of tenofovir fumarate.
  • the dissolution temperature in the step (1) is generally from room temperature to the reflux temperature of the solvent.
  • the present invention selects a solvent having a polarity of 0.1 or less as a crystallization solvent, and the second solvent is preferably one of the following: petroleum ether, n-hexane, Cyclohexane, isopentane, n-pentane, tridecylpentane.
  • the volume of the second solvent is generally from 10 to 50 mL/g based on the mass of tenofovir fumarate.
  • the drying is generally carried out at a temperature of 20 to 40 °C.
  • the crystalline form of tenofovir fumarate of the present invention can be used for the preparation of a medicament for the treatment of viral hepatitis B or AIDS (HIV/AIDS).
  • the preparation process of the formulation containing the crystalline form of tenofovir disoproxil fumarate and the preparation of the preparation will be specifically described below: Although tenofovir may be administered as a pure compound, it is preferably administered in the form of a pharmaceutical preparation.
  • the preparation of the present invention comprises a formulation of a crystalline form of tenofovir disoproxil fumarate and a pharmaceutically acceptable carrier.
  • Formulations suitable for oral administration of the present invention can be provided in the form of tablets, capsules/soft gelatin, granules, pills, and oral preparations.
  • the oral preparation containing the crystal form of tenofovir disoproxil fumarate according to the invention is prepared by mixing alpha crystal form of tenofovir disoproxil fumarate with one or several suitable excipients.
  • Uniform, round or shaped solid preparations prepared by formulation techniques can be prepared into oral tablets, dispersible tablets, film coated tablets, sublingual tablets, orally disintegrating tablets, enteric coated tablets, sustained release tablets, controlled release Tablets, instant release tablets, etc.
  • the oral preparation containing the crystal form of tenofovir fumarate of the present invention is prepared by the method of ⁇
  • the crystalline form of tenofovir disoproxil fumarate and one or more suitable adjuvants such as diluents, glidants, disintegrants, etc., are uniformly powdered or granulated in hollow capsules, which can be made into a hard Plastic bottles.
  • the formulation of the present invention comprises a formulation of a crystalline form of tenofovir disoproxil fumarate alpha and a pharmaceutically acceptable carrier.
  • Pharmaceutical carriers include diluents, disintegrants, preservatives, binders, glidants, and lubricants. These compositions may, if necessary, be a compound containing about 10 to 1000 mg of tenofovir disoproxil alpha form, preferably in the range of 100 to 300 mg.
  • the diluent in the pharmaceutical preparation of the present invention includes, but is not limited to, microcrystalline cellulose, lactose, pregelatinized starch, starch, dextrin, phosphoric acid 4 bow, carbonic acid 4 bow, mannitol, sorbitol, glucose, dextran and cyclodextrin. Fine
  • the binder in the pharmaceutical preparation of the present invention includes, but is not limited to, for example, starch syrup, povidone, hydroxypropyl hydrazine cellulose, hydroxypropyl cellulose, decyl cellulose, hydroxyethyl cellulose, gelatin, xanthan gum, and the like;
  • the lubricant in the pharmaceutical preparation of the present invention includes, but is not limited to, magnesium stearate, stearic acid, sodium stearate, sodium talc, sodium lauryl sulfate, and the like;
  • the disintegrant in the pharmaceutical preparation of the present invention includes, but is not limited to, carboxymethyl starch, sodium sulfonate, low-substituted hydroxypropyl cellulose, crospovidone, croscarmellose sodium, and Sodium carbamate sodium starch and pregelatinized starch;
  • the preservatives in the pharmaceutical preparation of the present invention include, but are not limited to, sodium benzoate, potassium sorbate, decyl p-hydroxybenzoate and ethyl p-hydroxybenzoate;
  • the buffering agent in the pharmaceutical preparation of the present invention includes, but is not limited to, phosphate buffer solution, citric acid, sodium citrate, acetate buffer solution, sodium phosphate and sodium hydroxide;
  • the antioxidant in the pharmaceutical preparation of the present invention includes, but is not limited to, sodium edetate, sodium sulfite, sodium metabisulfite, cystine and vitamins;
  • the taste regulating agent in the pharmaceutical preparation of the present invention includes, but is not limited to, fructose, sucrose, sodium saccharin, maltitol, orange flavor and strawberry flavor; Further, the pharmaceutical preparation of the present invention may further comprise other conventional and appropriate additives.
  • the pharmaceutically acceptable carrier in the above-mentioned preparation means that it may or may not be used as needed.
  • the same carrier such as a filler may be selected one or more.
  • the pharmaceutically acceptable carrier is a matrix or excipient that maintains the pharmaceutical dosage form, usually in accordance with different dosage forms or in combination, optionally including excipients or diluents, such as microcrystalline cellulose, in accordance with methods well known in the art.
  • lactose pregelatinized starch, starch, dextrin, phosphoric acid 4 bow, carbonic acid 4 bow, mannitol, sorbitol, glucose, dextran and cyclodextrin
  • a binder such as starch
  • a lubricant such as magnesium stearate , one or more of stearic acid, sodium stearate, talc and sodium lauryl sulfate
  • a disintegrant such as carboxymethyl starch, sodium methylcellulose, low substituted hydroxyl
  • preservatives such as sodium benzoate, sorbic acid Potassium,
  • the invention can be prepared by the following methods: (e.g., ordinary tablets)
  • the tenofovir disoproxil is separately mixed with the pharmaceutical ingredient to obtain preferred handling and processing properties, and the pharmaceutical ingredients which can be used include fillers, lubricants, disintegrating agents and other pharmaceutically acceptable excipients.
  • the pharmaceutical ingredients which can be used include fillers, lubricants, disintegrating agents and other pharmaceutically acceptable excipients.
  • a certain amount of the binder solution is added, wet granulation, the obtained granules are dried to a certain extent, a lubricant is added, and the tablets are pressed into a certain size and size to obtain a common tablet of tenofovir.
  • the invention can be prepared by the following methods: (e.g., an anthraquinone)
  • the tenofovir disoproxil is separately mixed with the pharmaceutical ingredient to obtain a preferred treatment and processing property, sieved, and directly placed in a hollow capsule to obtain a capsule.
  • a certain amount of the binder solution is added to the mixed components, wet granulation, and the obtained granules are dried to a certain extent, and the whole granules are placed in a hollow capsule to obtain a capsule.
  • the tenofovir disoproxil fumarate 0 crystal form prepared by the invention is superior to the conventional crystal form in terms of dissolution, and can be better absorbed by the human body. Moreover, the preparation method of the invention is simple and suitable for industrial production. Fourth, the description of the drawings
  • Figure 1 is a powder X-ray diffraction spectrum of tenofovir disoproxil fumarate ⁇ crystal form.
  • Figure 2 is a differential thermal analysis of the crystalline form of tenofovir disoproxil fumarate.
  • Figure 3 is an infrared spectrum of the crystalline form of tenofovir disoproxil fumarate. V. Specific implementation methods
  • the XRD characteristic peaks of the obtained crystal form are expressed at about 2, 11, 7.8, 8.1, 9.8, 10.5, 10.9, 11.6, 11.9, 13.7, 14.3, 14.7, 15.6, 16.1, 16.6, 16.8, 17.9, 18.4, 19.2, 20.4, 21.2, 21.6, 22.5, 22.7, 23.4, 24.3, 25.4 and 26.4.
  • Infrared spectroscopy (IR) absorption bands are approximately 3337, 3198, 2986 ⁇ 2935, 1764, 1661, and 1621 cm" 1
  • the DSC has an endothermic peak at about 117.4, starting at about 115.5 °C.
  • the mixture was slowly stirred at room temperature for 30 minutes, and then slightly cooled to about 15 ° C, and after 1 hour of incubation, suction filtration was carried out, and vacuum drying was carried out for 10 hours at room temperature to obtain about 47 g of the final product.
  • the yield is 94% and the purity is over 99%.
  • the XRD characteristic peaks of the obtained crystal form are expressed at about 2, 11, 7.8, 8.1, 9.8, 10.5, 10.9, 11.6, 11.9, 13.7, 14.3, 14.7, 15.6, 16.1, 16.6, 16.8, 17.9, 18.4, 19.2, 20.4, 21.2, 21.6, 22.5, 22.7, 23.4, 24.3, 25.4 and 26.4.
  • Infrared spectroscopy (IR) absorption bands are approximately 3337, 3198, 2986 ⁇ 2935, 1764, 1661, and 1621 cm" 1
  • the DSC has an endothermic peak at about 117.4, starting at about 115.5 °C.
  • Example 4 and Example 5 The raw materials of the crystal form of tenofovir disoproxil fumarate from the United States Gilead Science were respectively prepared according to the methods of Example 4 and Example 5 (labeled as tablet b and capsule b), and the same as the ⁇ crystal form.
  • the method is as follows: 900ml water as dissolution medium, rotary dissolution, rotation speed is 75r/min, according to the Chinese Pharmacopoeia 2005 edition two appendix XC first method, sampling at 30min, filtering through 0. 45 ⁇ ⁇ microporous membrane The filtrate was used as a test solution.
  • the appropriate amount of the tenofovir disoproxil reference substance was accurately weighed, dissolved in water, and then diluted to a lmg/ml with a mobile phase, and filtered through a 0.54 m microporous membrane to obtain a reference solution.
  • Peak area of the test sample X Concentration of the reference substance X 900

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une forme cristalline α du Ténofovir disoproxil fumarate, un procédé pour la préparer et son utilisation. Dans le cas de rayonnements Cu-Ka, un spectre de diffraction des rayons X sur poudre, exprimé en degrés 2Θ, indique des pics caractéristiques d'environ 7.1, 7.8, 8.1, 9.8, 10.5, 10.9, 1 1.6, 1 1.9, 13.7, 14.3, 14.7, 15.6, 16.1, 16.6, 16.8, 17.9, 18.4, 19.2, 20.4, 21.2, 21.6, 22.5, 22.7, 23.4, 24.3, 25.4 and 26.4. La forme cristalline α du Ténofovir disoproxil fumarate préparée présente un net avantage sur la forme cristalline antérieur en termes de vitesse de dissolution, et présente une meilleure capacité d'absorption au niveau du corps. Le procédé de préparation est simple et peut être adapté en vue d'une production industrialisée.
PCT/CN2011/070142 2010-08-30 2011-01-10 FORME CRISTALLINE α DU TÉNOFOVIR DISOPROXIL FUMARATE, PROCÉDÉ POUR LA PRÉPARER ET SON UTILISATION WO2012027972A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010102666023A CN101948485B (zh) 2010-08-30 2010-08-30 富马酸替诺福韦酯α晶型及其制备方法和应用
CN201010266602.3 2010-08-30

Publications (1)

Publication Number Publication Date
WO2012027972A1 true WO2012027972A1 (fr) 2012-03-08

Family

ID=43452126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/070142 WO2012027972A1 (fr) 2010-08-30 2011-01-10 FORME CRISTALLINE α DU TÉNOFOVIR DISOPROXIL FUMARATE, PROCÉDÉ POUR LA PRÉPARER ET SON UTILISATION

Country Status (2)

Country Link
CN (1) CN101948485B (fr)
WO (1) WO2012027972A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626803B (zh) * 2012-08-23 2017-12-15 四川海思科制药有限公司 替诺福韦二吡呋酯的固体及其制备方法和用途
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
CN103705478B (zh) * 2013-12-23 2020-02-07 浙江华海药业股份有限公司 含有富马酸替诺福韦二吡呋酯的口服片剂
KR101677433B1 (ko) * 2014-10-29 2016-11-21 주식회사 퍼슨 이온 교환수지를 이용한 개선된 테노포비르 디소프록실 푸마레이트 합성방법 및 이를 이용한 구강 붕해 필름(odf)제형의 제조방법
CN106008603B (zh) * 2016-06-03 2018-12-11 东北制药集团股份有限公司 一种替诺福韦二吡呋酯及其富马酸盐的制备方法
CN107998094A (zh) * 2016-10-31 2018-05-08 顾世海 一种富马酸替诺福韦酯缓释片及其制备方法
KR101805684B1 (ko) * 2016-11-11 2018-01-11 주식회사 퍼슨 테노포비르 디소프록실 푸마레이트를 이용한 구강용해 필름(odf)제형 및 이의 제조방법
CN108948083A (zh) * 2017-05-17 2018-12-07 上海科胜药物研发有限公司 一种富马酸替诺福韦二吡呋酯新晶型及其制备方法
CN109942634A (zh) * 2019-01-24 2019-06-28 深圳科兴药业有限公司 一种富马酸替诺福韦二吡呋酯的晶型i及制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013086A1 (fr) * 2005-07-26 2007-02-01 Hetero Drugs Limited Nouveaux polymorphes de tenofovir disoproxil fumarate
CN101066980A (zh) * 2007-05-08 2007-11-07 黑龙江加州国际投资咨询有限公司 富马酸泰诺福韦酯新晶型及其药用制剂
WO2009064174A1 (fr) * 2007-11-14 2009-05-22 Ultimorphix Technologies B.V. Forme polymorphe du ténofovir disoproxil fumarate, son procédé de préparation et son utilisation
WO2009130437A1 (fr) * 2008-04-25 2009-10-29 Cipla Limited Forme cristalline du ténofovir disoproxil et son procédé de préparation
CN101781335A (zh) * 2010-03-04 2010-07-21 福建广生堂药业有限公司 富马酸替诺福韦酯的新晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737273B2 (en) * 2005-07-26 2010-06-15 Hetero Drugs Limited Process for acyclic phosphonate nucleotide analogs
WO2010026603A2 (fr) * 2008-09-05 2010-03-11 Matrix Laboratories Limited Nouveaux sels d’amine de ténofovir, leur procédé de production et leur utilisation dans la production de ténofovir disoproxil

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013086A1 (fr) * 2005-07-26 2007-02-01 Hetero Drugs Limited Nouveaux polymorphes de tenofovir disoproxil fumarate
CN101066980A (zh) * 2007-05-08 2007-11-07 黑龙江加州国际投资咨询有限公司 富马酸泰诺福韦酯新晶型及其药用制剂
WO2009064174A1 (fr) * 2007-11-14 2009-05-22 Ultimorphix Technologies B.V. Forme polymorphe du ténofovir disoproxil fumarate, son procédé de préparation et son utilisation
WO2009130437A1 (fr) * 2008-04-25 2009-10-29 Cipla Limited Forme cristalline du ténofovir disoproxil et son procédé de préparation
CN101781335A (zh) * 2010-03-04 2010-07-21 福建广生堂药业有限公司 富马酸替诺福韦酯的新晶型及其制备方法

Also Published As

Publication number Publication date
CN101948485B (zh) 2012-07-25
CN101948485A (zh) 2011-01-19

Similar Documents

Publication Publication Date Title
WO2012027972A1 (fr) FORME CRISTALLINE α DU TÉNOFOVIR DISOPROXIL FUMARATE, PROCÉDÉ POUR LA PRÉPARER ET SON UTILISATION
WO2015176602A1 (fr) Complexe de ténofovir alafénamide, son procédé de préparation et utilisation
JP6359971B2 (ja) イバブラジン塩酸塩の形態ｉｖ
CN105646584B (zh) 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途
TWI737861B (zh) N-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺游離鹼半水合物、製造方法及其用途
CN110054624B (zh) 盐酸小檗碱与咖啡酸共晶物及制备方法和其组合物与用途
TWI650316B (zh) Ｍｅｋ抑制劑之製備及包含ｍｅｋ抑制劑之調配物
ES2361796T3 (es) Composiciones en comprimidos que contienen atazanavir.
TWI447110B (zh) 苯并咪唑化合物之結晶
TW200812943A (en) Processes for preparation of tigecycline crystalline forms I and II
JP2012507496A (ja) レナリドマイドの結晶形およびその調製方法
KR20070007196A (ko) 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법
WO2015139386A1 (fr) Canagliflozine monohydratée et sa forme cristalline, son procédé de préparation et son utilisation
US20160046603A1 (en) Crystalline Forms of D-Glucitol, 1-Deoxy-1-(Methylamino)-, 1-(6-Amino-3,5-Difluoropyridine-2-Yl)-8-Chloro-6-Fluoro-1,4-Dihydro-7-(3-Hydroxyazetidin-1-Yl)-4-Oxo-3-Quinolinecarboxylate
WO2005113492A1 (fr) Sels d'ambroxol analogues de cysteine, procedes d'elaboration et utilisations
CN106176771B (zh) 一种拉米夫定-替诺福韦复方片及其制备方法
JP2021121645A (ja) １５β−ヒドロキシ−酢酸オサテロンの結晶多形
PT2170292E (pt) Composições de comprimido contendo atazanavir
IL167659A (en) Crystalline sibutramine methanesulfonate hemihydrate, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2019011349A1 (fr) Forme cristalline b de fenlean (flz), procédé de préparation, composition et utilisation de celle-ci
JP2016006090A (ja) レボノルゲストレルの結晶多形α及びその製造方法
CN113214207B (zh) 橙皮素与甜菜碱共晶物a及制备方法和其组合物与用途
CN113214209B (zh) 橙皮素与卡马西平共晶物及制备方法和其组合物与用途
JP5809368B2 (ja) レボノルゲストレルの結晶多形β及びその製造方法
CN105399725B (zh) 曲格列汀化合物其盐、晶体、药物组合物和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11821002

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11821002

Country of ref document: EP

Kind code of ref document: A1